Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniel Houtsma
Observed names:
D Houtsma,
D. Houtsma,
Daniël Houtsma,
Houtsma, Daniel
Institution:
Haga Hospital
Observed institutions:
Leiden University Medical Center,
Haukeland University Hospital,
Haga Hospital,
Swiss Group For Clinical Cancer Research
OpenAlex ID:
A5040146151
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
2015
·
Stefanie de Groot
, Maaike PG Vreeswijk
, et al.
·
BMC Cancer
·
286
PDF
Familial Paget's disease in The Netherlands: Occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations
2004
·
E. W. M. Eekhoff
, M. Karperien
, et al.
·
Arthritis & Rheumatism
·
107
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
2014
·
Duveken B. Y. Fontein
, Daniel Houtsma
, et al.
·
Breast Cancer Research and Treatment
·
38
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
2024
·
Nadia Harbeck
, Eva Ciruelos
, et al.
·
Nature Medicine
·
14
PDF
MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study
2026
·
Fleur M Louis
, Anna van der Voort
, et al.
·
The Lancet Oncology
·
12
Prospective evaluation of genomics-guided off-label treatment
2026
·
K. Verkerk
, A. C. Spiekman
, et al.
·
Nature
·
11
PDF
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
2023
·
Jens Huober
, Patrik Weder
, et al.
·
JAMA Oncology
·
7
198 Specific Adverse Events Predict Survival Benefit in Early Breast Cancer Patients Treated with Exemestane in the Dutch/Belgian TEAM Trial
2012
·
D. Fontein
, D. Houtsma
, et al.
·
European Journal of Cancer
·
1
Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer
2026
·
N. de Gruil
, A. F. de Groot
, et al.
·
Breast Cancer Research
Low Rate of Toxicity in Older Cancer Patients Treated With Immunotherapy
2019
·
D. Van Der Ziel
, N. De Glas
, et al.
·
Journal of Geriatric Oncology
Additional file 1: Table S1. of The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
2015
·
de Groot, Stefanie
, Vreeswijk, Maaike
, et al.
·
Figshare
Abstract P4-16-12: CARE: A pilot study of the effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in breast cancer patients
2013
·
S de Groot
, MPG Vreeswijk
, et al.
·
Cancer Research
Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial.
2012
·
Daniel Houtsma
, Duveken Fontein
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
15
Citation count:
476
H-index:
7
I10-index:
6
Year
Topic
Type